Skip to main content

Table 1 Outcomes of randomised trials

From: Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

Outcome Number of trials Number of patients Percentage with MMF Percentage with cyclophosphamide Relative benefit or risk (95% CI) NNT (95% CI)
Efficacy       
   Complete response 4 266 36 23 1.5 (1.1 to 2.1) 7.6 (4.2 to 43)
   Complete or partial response 5 306 66 54 1.2 (1.03 to 1.4) 8.0 (4.3 to 60)
   Subsequent relapse 2 102 27 34 0.8 (0.4 to 1.4)  
Adverse events       NNTp (95% CI)
   Death 5 306 0.7 7.8 0.2 (0.07 to 0.7) 14 (8 to 48)
   Hospital admission 2 220 1.7 15 0.1 (0.04 to 0.5) 7.4 (4.8 to 16)
   Adverse event discontinuations 3 246 1.6 5.6 0.3 (0.08 to 1.4)  
   All infections 4 280 39 73 0.5 (0.4 to 0.7) 3.0 (2.3 to 4.4)
   Serious infections 4 304 3.9 15 0.3 (0.1 to 0.6) 8.7 (5.5 to 21)
   Leucopaenia 3 122 1.6 25 0.1 (0.03 to 0.5) 4.3 (2.9 to 8.3)
   Amenorrhea 5 312 1.9 12 0.2 (0.08 to 0.6) 9.5 (6.2 to 20)
   Hair loss 3 240 0.0 16 0.1 (0.01 to 0.4) 6.4 (4.4 to 11)
       NNH (95% CI)
   Diarrhoea 4 260 16 4.0 4.0 (1.5 to 10) 8.5 (5.3 to 21)
  1. CI, confidence interval; MMF, mycophenolate mofetil; NNH, number needed to harm; NNT, number needed to treat; NNTp, number needed to treat to prevent one event.
\